+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study

Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study

Chinese Medical Journal 131(2): 156-160

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a treatable autoimmune neurologic syndrome that occurs with or without tumor association. However, some severe cases are refractory to systemic immunotherapy. This pilot study aimed to evaluate the utility and safety of intrathecal methotrexate injection for severe patients with anti-NMDAR encephalitis who did not respond to first-line immunotherapy. Intrathecal injections with methotrexate and dexamethasone were performed weekly in four legible patients within consecutive 4 weeks. Cerebrospinal fluid (CSF) was collected at baseline and each time of intrathecal injection for identification of anti-NMDAR antibody titers. Significant clinical improvement was observed in three patients associated with a stepwise decrease of CSF anti-NMDAR antibody titers (maximum: 1/320 to minimum: 1/10). After 2 months of follow-up, they were able to follow simple commands and had appropriate interactions with people (modified Rankin scale [mRS] of 0-2). At 12 months of follow-up, they all had returned to most activities of daily life (mRS of 0), and no relapses were reported. One patient showed no clinical improvement and died of neurologic complications. Intrathecal treatment may be a potentially useful supplementary therapy in severely affected patients with anti-NMDAR encephalitis. Further large cohort study and animal experiment may help us elaborate the utility of intrathecal injection of methotrexate and its mechanism of action.

(PDF same-day service: $19.90)

Accession: 065660591

Download citation: RISBibTeXText

PMID: 29336363

DOI: 10.4103/0366-6999.222327

Related references

Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Developmental Medicine and Child Neurology 57(1): 95-99, 2015

Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. Mediators of Inflammation 2017: 6361479-6361479, 2017

Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurology 70(1): 117-119, 2013

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: experience with six pediatric patients. Potential efficacy of methotrexate. Revista de Neurologia 57(9): 405-410, 2014

A case of anti-N-methyl-D-aspartate receptor encephalitis with ovarian teratoma showing excellent recovery with decreasing of anti-N-methyl-D-aspartate receptor antibody. Rinsho Shinkeigaku 51(7): 499-504, 2011

Immunotherapy strategy for 35 cases of severe anti-N-methyl-D-aspartate receptor encephalitis. Zhonghua Yi Xue Za Zhi 96(13): 1035-1039, 2016

Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis. Journal of Neuroimmunology 297: 141-147, 2016

Clinical Characteristics and Prognosis of Severe Anti-N-methyl-D-aspartate Receptor Encephalitis Patients. Neurocritical Care, 2018

Clinical diagnosis and treatment of pediatric anti-N-methyl-D-aspartate receptor encephalitis: A single center retrospective study. Experimental and Therapeutic Medicine 16(2): 1442-1448, 2018

Multistage neurorehabilitation of an adolescent with severe anti-N-methyl-D-aspartate receptor encephalitis: a case report. International Journal of Rehabilitation Research. Internationale Zeitschrift für Rehabilitationsforschung. Revue Internationale de Recherches de Readaptation, 2018

Efficacy and safety of cyclophosphamide as a sequential immunotherapy drug for anti-N-methyl-D-aspartate receptor encephalitis in children. Zhongguo Dang Dai Er Ke Za Zhi 19(6): 668-671, 2017

Recognition and Treatment of Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Clinical Pediatric Emergency Medicine 16(1): 3-10, 2015

Severe childhood encephalopathy with dyskinesia and prolonged cognitive disturbances: evidence for anti-N-methyl-D-aspartate receptor encephalitis. Developmental Medicine and Child Neurology 52(5): E78-E82, 2010

Early operative treatment of anti-N-methyl D-aspartate (anti-NMDA) receptor encephalitis in a patient with ovarian teratoma. Clinical and Experimental Obstetrics & Gynecology 42(6): 819-821, 2016

Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis. JAMA Neurology 73(10): 1251-1253, 2016